TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05651919

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.

Intervention type: BEHAVIORAL
Intervention: quality of life Questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems.

Intervention type: BEHAVIORAL
Intervention: quality of life Questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems.
Study: NCT05087992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905711
Description: BI 905711
Study: NCT05651919

Intervention type: BEHAVIORAL
Intervention: quality of life Questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about quality of life.~This is a descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. This decision results into a 1-digit number that expresses the level selected for that dimension. Each patient's health state is referred to in terms of a 5-digit code;~Levels of perceived problems are coded as follows:~* Level 1 is coded as a '1' (indicating no problem)~* Level 2 is coded as a '2' (indicating some problems)~* Level 3 is coded as a '3' (indicating extreme problems) For example, state 11223 indicates no problems with mobility and self-care, no problems with performing usual activities, moderate pain or discomfort and extreme anxiety or depression, while state 11111 indicates no problems.

Intervention type: BEHAVIORAL
Intervention: Diet habits questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients.

Intervention type: BEHAVIORAL
Intervention: Diet habits questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients.

Intervention type: BEHAVIORAL
Intervention: Diet habits questionnaire
Description: During the routine medical visit, the patient will be asked to fill in a short questionnaire about his diet habits.~This is an exploratory questionnaire that describes and quantifies the foods (pro- or anti-inflammatory) ingested by patients.
Study: NCT05087992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI
Study: NCT06437938

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement A: Wasabi leaf powder (product of BIOGENA GmbH & Co KG)
Description: To be taken according to the information in the study protocol/patient information leaflet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement B: Berberin Phytoactive Gold (product of BIOGENA GmbH & Co KG)
Description: To be taken according to the information in the study protocol/patient information leaflet.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement C: DiaPhyt® Formula 3.0 (product of BIOGENA GmbH & Co KG)
Description: To be taken according to the information in the study protocol/patient information leaflet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group 1: Placebo capsules corresponding to DiaPhyt® Formula 3.0/Berberin Phytoactive Gold
Description: To be taken according to the information in the study protocol/patient information leaflet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group 2: Placebo powder corresponding to Wasabi leaf powder
Description: To be taken according to the information in the study protocol/patient information leaflet.
Study: NCT04786600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signatera ctDNA assay
Description: Subjects will be tested with the Signatera ctDNA assay every 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pre-specified sequence of FDA-approved drugs and drug combinations
Description: Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pre-specified sequence of FDA-approved drugs and drug combinations
Description: Subjects will receive treatment with a pre-specified sequence of FDA-approved drugs and drug combinations
Study: NCT05019105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALKS 1140
Description: Active oral dose of ALKS 1140
Study: NCT06308770

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants receive fatigue booklets from two charitable organisations providing information on fatigue, sleep, energy conservation, exercise and stress to help manage fatigue.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants receive fatigue booklets from two charitable organisations providing information on fatigue, sleep, energy conservation, exercise and stress to help manage fatigue.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants receive fatigue booklets from two charitable organisations providing information on fatigue, sleep, energy conservation, exercise and stress to help manage fatigue.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 week FMP
Description: Participants attend 3 once weekly live online group interventions with a final intervention 8 weeks later.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 week FMP
Description: Participants attend 6 once weekly live online group interventions with a final intervention 8 weeks later.
Study: NCT05632679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized music intervention
Description: participants who are randomly selected to this group will choose three set of music they prefer among the available selection of instrumental music in the application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected audio book
Description: participants who are randomly selected to this group will choose one audio book they prefer among the available selection of audio books on the tablet
Study: NCT05809531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study: NCT06772220

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid 1 MG
Description: Folic Acid 1mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B6 25 MG
Description: Vitamin B6, 25mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12, 1,000 ug per day
Study: NCT06772831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal by Distancing
Description: Reappraisal-by-distancing treatment. Patients meet 2 times a week for 6 weeks to learn reappraisal by distancing through repeated practice with negative emotional pictures. The therapist will help model and shape the technique.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Downregulate condition
Description: Patients either meet 2x a week for 6- weeks to gain added practice, under the guidance of a therapist, using their customary emotion regulatory strategies to downregulate their negative reactions to aversive pictures.
Study: NCT06772818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Oral Tablet
Study: NCT06772259

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palm Stimulator
Description: The apparatus is 1.6 cm in diameter and 4 cm long. It has a cylindrical, non-slippery and easy-to-grasp structure for maximum contact with the palm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon
Description: The cartoon was projected on a blank wall in the intervention room with a projection device. The cartoon was played in preparation for the PIK procedure and children were allowed to watch it until the procedure was completed.
Study: NCT06772961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: In this study, the traditional acupoints Taiyuan (LU9) on the lung meridian and Hegu (LI4) on the large intestine meridian were selected. The lung and large intestine meridians are interconnected, so the combined application of Taiyuan and Hegu acupoints with TEAS can produce a synergistic effect. This combination enhances the replenishment of lung qi, promotes the flow of meridians, regulates qi, and disseminates lung functions. It can stimulate effective breathing in patients, thus positively influencing the improvement of their oxygen saturation levels.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care plan
Description: Conventional care plan
Study: NCT05700123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-Office Hysteroscopy
Description: In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-Office Hysteroscopy
Description: In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-Office Hysteroscopy
Description: In-office hysteroscopic procedures were conducted using a 5mm continuous flow Office Hysteroscope using a vaginoscopic, no-touch, approach
Study: NCT05780385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasotracheal intubation
Description: patients requiring tracheal intubation receive nasotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation
Description: patients requiring tracheal intubation receive orotracheal intubation
Study: NCT05885997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported HBPM program plus multifaceted implementation strategy
Description: Supported HBPM Program:~* Patients are loaned a wireless home BP device or use their own device~* Navigator or app support for onboarding and engaging patients in HBPM~* Nursing or app support for monitoring and triaging home BP data for extreme readings~* EHR integration of order for program and home BP data, with weekly feedback of home BP results to clinicians within the EHR~Multifaceted implementation strategy:~* Clinician education about the benefits of the program as well as training in how to refer and manage patients who are enrolled~* Prompts and reminders to increase clinician referrals~* Instructional materials for patients and clinicians~* Problem-solving meetings to tailor implementation for individual practices
Study: NCT05537714

Intervention type: BEHAVIORAL
Intervention: Qualitative interviews/focus groups
Description: We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.

Intervention type: BEHAVIORAL
Intervention: Qualitative interviews/focus groups
Description: We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
Study: NCT05192369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: CTP-543 12 mg (1 x 12 mg tablet), dosed with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: CTP-543 48 mg (4 x 12 mg tablet) dosed with water
Study: NCT05087992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study: NCT05885997

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study: NCT05192369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin (1 x 400 mg tablet) dosed with water
Study: NCT05885997

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care
Study: NCT05192369

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1 tablet) dosed with water
Study: NCT05087992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study: NCT05443204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortimel energy
Description: Standard nutritional oral supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrision Advanced Diason Energy HP
Description: Specifc nutritional oral supplement in diabetics patients
Study: NCT05984550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMN
Description: NMN (Nicotinamide Mononucleotide) is a naturally occurring bioactive nucleotide with the full name of Nicotinamide mononucleotide. Its structure can be divided into α and β Two isomers, of which only β- NMN is a naturally occurring form with biological activity.~In human body, NMN is the precursor of NAD+(Nicotinamide adenine dinucleotide, also known as coenzyme I), and its function is mainly reflected through NAD+.
Study: NCT05253391

Intervention type: OTHER
Intervention: Routine care
Description: The investigator takes care of the patient according to the protocol in force in his department and decides on the final orientation of the patient (transfer to intensive care unit/ICU, hospitalization or home discharge).~No recommendations or instructions are given to the investigators. Each investigator is free to decide on his care and the terms of transfer, hospitalization and discharge.
Study: NCT04918823

Intervention type: DRUG
Group type: OTHER
Intervention: Restasis
Description: Subject will use one drop of Restasis in the lens before insertion
Study: NCT06081894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT05090124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab 40mg, will be administered as a subcutaneous injection once fortnightly on four occasions. The actual Adalimumab product selected at site will be dictated by what is used in standard care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% for injection will be used as a placebo. An equal volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection once fortnightly on four occasions.
Study: NCT05349500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OA CARE Intervention
Description: Once assigned, participants will be contacted by the OA CARE Navigator to coordinate initiating a YMCA Medical Membership. Then, YMCA personnel will contact the participant to schedule the first Weight Loss Program (Program) group session. The Program will be delivered in groups with other OA CARE participants. Participants will also have access to all exercise facilities and programs at the YMCA during the study, and will be assigned a YMCA health coach.~After initiation of the YMCA Medical Membership, the OA CARE Navigator will discuss participant's interests in referrals to other services related to osteoarthritis (OA) management. The Navigator will provide the participant's primary care provider (PCP) with a summary of this discussion and help the participant connect to any programs or resources that do not require provider referrals.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care control group
Description: Participants assigned to the usual care group will receive no additional treatment from the study for about 12 months. However, this group will be offered a 12-month Medical Membership to a local YMCA after completing the final assessment.
Study: NCT06414018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: alfentanil 10ug/kg is used for anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: alfentanil 10ug/kg is used for anesthesia induction
Study: NCT06115499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06545162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 80mg single dose
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 120mg single dose
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 160mg single dose
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 80mg Q2W
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 120mg Q2W
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 160mg Q2W
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 200mg Q2W
Description: Subcutaneous injection of CPX101 or placebo
Study: NCT04478825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S
Description: BBT-401-1S, 8 weeks, once a day
Study: NCT04992975

Intervention type: OTHER
Intervention: MRI at 7T
Description: MRI at 7T

Intervention type: OTHER
Intervention: MRI at 7T
Description: MRI at 7T
Study: NCT06115499

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05272865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Description: Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Description: Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Description: Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Description: Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.